Product Description: Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor.
Applications: Cancer-Kinase/protease
Formula: C24H24Br2ClN9O3
References: [1]Shevan Silva, Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy. Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA./[2]Adam V. Patterson, Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.
CAS Number: 1636180-98-7
Molecular Weight: 681.77
Compound Purity: 99.26
Research Area: Cancer
Solubility: DMSO : ≥ 33 mg/mL
Target: EGFR
Deutsch
English
